Cargando…
Developmental Evaluation of Infants Who Have Received Tadalafil in Utero for Fetal Growth Restriction
To assess the long-term effects of tadalafil, a therapeutic agent for fetal growth restriction (FGR), we evaluated the developmental progress of 1.5-year-old infants whose mothers had taken tadalafil during pregnancy. Twenty-four infants were assessed. We evaluated infant body weight, height, and he...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7291198/ https://www.ncbi.nlm.nih.gov/pubmed/32413997 http://dx.doi.org/10.3390/jcm9051448 |
_version_ | 1783545854107320320 |
---|---|
author | Maki, Shintaro Kato, Ineko Enomoto, Naosuke Takakura, Sho Nii, Masafumi Tanaka, Kayo Tanaka, Hiroaki Hori, Shinsuke Matsuda, Kana Ueda, Yukito Sawada, Hirofumi Hirayama, Masahiro Sudo, Akihiro Ikeda, Tomoaki |
author_facet | Maki, Shintaro Kato, Ineko Enomoto, Naosuke Takakura, Sho Nii, Masafumi Tanaka, Kayo Tanaka, Hiroaki Hori, Shinsuke Matsuda, Kana Ueda, Yukito Sawada, Hirofumi Hirayama, Masahiro Sudo, Akihiro Ikeda, Tomoaki |
author_sort | Maki, Shintaro |
collection | PubMed |
description | To assess the long-term effects of tadalafil, a therapeutic agent for fetal growth restriction (FGR), we evaluated the developmental progress of 1.5-year-old infants whose mothers had taken tadalafil during pregnancy. Twenty-four infants were assessed. We evaluated infant body weight, height, and head circumference, and performed the Kyoto Scale of Psychological Development (KSPD) test, a standardized developmental assessment covering Postural–Motor (P–M), Cognitive–Adaptive (C–A), and Language-Social (L–S) functions. The sum score was converted to a developmental quotient (DQ). The mean gestational week of the included cases was 36.1 (29–39) weeks, and the mean birth weight was 1841 (874–2646) g. Twenty-one and 20 out of the 24 cases, respectively, attained body weight and height similar to those of age-matched normal infants (within the 3rd percentile); all cases caught up in head circumference. KSPD was performed for 18 cases at 1.5 years of corrected age. The mean DQ scores were 87 (in total): 82 in P–M, 90 in C–A, and 88 in L–S. The total DQ score in one case (5.6%) was less than 70, and ranged from 70 to 85 in five cases (27.7%), and was more than 85 in 11 cases (61.1%). The growth and development of infants born of tadalafil-treated mothers seem to show good progress at a corrected age of 1.5 years. |
format | Online Article Text |
id | pubmed-7291198 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-72911982020-06-17 Developmental Evaluation of Infants Who Have Received Tadalafil in Utero for Fetal Growth Restriction Maki, Shintaro Kato, Ineko Enomoto, Naosuke Takakura, Sho Nii, Masafumi Tanaka, Kayo Tanaka, Hiroaki Hori, Shinsuke Matsuda, Kana Ueda, Yukito Sawada, Hirofumi Hirayama, Masahiro Sudo, Akihiro Ikeda, Tomoaki J Clin Med Article To assess the long-term effects of tadalafil, a therapeutic agent for fetal growth restriction (FGR), we evaluated the developmental progress of 1.5-year-old infants whose mothers had taken tadalafil during pregnancy. Twenty-four infants were assessed. We evaluated infant body weight, height, and head circumference, and performed the Kyoto Scale of Psychological Development (KSPD) test, a standardized developmental assessment covering Postural–Motor (P–M), Cognitive–Adaptive (C–A), and Language-Social (L–S) functions. The sum score was converted to a developmental quotient (DQ). The mean gestational week of the included cases was 36.1 (29–39) weeks, and the mean birth weight was 1841 (874–2646) g. Twenty-one and 20 out of the 24 cases, respectively, attained body weight and height similar to those of age-matched normal infants (within the 3rd percentile); all cases caught up in head circumference. KSPD was performed for 18 cases at 1.5 years of corrected age. The mean DQ scores were 87 (in total): 82 in P–M, 90 in C–A, and 88 in L–S. The total DQ score in one case (5.6%) was less than 70, and ranged from 70 to 85 in five cases (27.7%), and was more than 85 in 11 cases (61.1%). The growth and development of infants born of tadalafil-treated mothers seem to show good progress at a corrected age of 1.5 years. MDPI 2020-05-13 /pmc/articles/PMC7291198/ /pubmed/32413997 http://dx.doi.org/10.3390/jcm9051448 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Maki, Shintaro Kato, Ineko Enomoto, Naosuke Takakura, Sho Nii, Masafumi Tanaka, Kayo Tanaka, Hiroaki Hori, Shinsuke Matsuda, Kana Ueda, Yukito Sawada, Hirofumi Hirayama, Masahiro Sudo, Akihiro Ikeda, Tomoaki Developmental Evaluation of Infants Who Have Received Tadalafil in Utero for Fetal Growth Restriction |
title | Developmental Evaluation of Infants Who Have Received Tadalafil in Utero for Fetal Growth Restriction |
title_full | Developmental Evaluation of Infants Who Have Received Tadalafil in Utero for Fetal Growth Restriction |
title_fullStr | Developmental Evaluation of Infants Who Have Received Tadalafil in Utero for Fetal Growth Restriction |
title_full_unstemmed | Developmental Evaluation of Infants Who Have Received Tadalafil in Utero for Fetal Growth Restriction |
title_short | Developmental Evaluation of Infants Who Have Received Tadalafil in Utero for Fetal Growth Restriction |
title_sort | developmental evaluation of infants who have received tadalafil in utero for fetal growth restriction |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7291198/ https://www.ncbi.nlm.nih.gov/pubmed/32413997 http://dx.doi.org/10.3390/jcm9051448 |
work_keys_str_mv | AT makishintaro developmentalevaluationofinfantswhohavereceivedtadalafilinuteroforfetalgrowthrestriction AT katoineko developmentalevaluationofinfantswhohavereceivedtadalafilinuteroforfetalgrowthrestriction AT enomotonaosuke developmentalevaluationofinfantswhohavereceivedtadalafilinuteroforfetalgrowthrestriction AT takakurasho developmentalevaluationofinfantswhohavereceivedtadalafilinuteroforfetalgrowthrestriction AT niimasafumi developmentalevaluationofinfantswhohavereceivedtadalafilinuteroforfetalgrowthrestriction AT tanakakayo developmentalevaluationofinfantswhohavereceivedtadalafilinuteroforfetalgrowthrestriction AT tanakahiroaki developmentalevaluationofinfantswhohavereceivedtadalafilinuteroforfetalgrowthrestriction AT horishinsuke developmentalevaluationofinfantswhohavereceivedtadalafilinuteroforfetalgrowthrestriction AT matsudakana developmentalevaluationofinfantswhohavereceivedtadalafilinuteroforfetalgrowthrestriction AT uedayukito developmentalevaluationofinfantswhohavereceivedtadalafilinuteroforfetalgrowthrestriction AT sawadahirofumi developmentalevaluationofinfantswhohavereceivedtadalafilinuteroforfetalgrowthrestriction AT hirayamamasahiro developmentalevaluationofinfantswhohavereceivedtadalafilinuteroforfetalgrowthrestriction AT sudoakihiro developmentalevaluationofinfantswhohavereceivedtadalafilinuteroforfetalgrowthrestriction AT ikedatomoaki developmentalevaluationofinfantswhohavereceivedtadalafilinuteroforfetalgrowthrestriction |